Literature DB >> 3084645

Induction of protective immunity against Schistosoma mansoni by a nonliving vaccine. II. Response of mouse strains with selective immune defects.

S L James, L A DeBlois.   

Abstract

The efficacy of a new vaccination procedure against Schistosoma mansoni, involving intradermal injection of nonliving antigen combined with the bacterial adjuvant Mycobacterium bovis strain bacillus Calmette Guérin, was tested in several strains of mice. Development of protection against subsequent infection was compared with in vivo skin test reactivity and in vitro humoral reactivity to soluble and surface-associated schistosome antigens. Significant levels of resistance and immune response were displayed by many inbred mouse strains, including C57BL/6J, C3H/HeN, and CBA/J, as well as outbred Swiss-Webster mice. However, no definite correlation was observed between the level of any particular immune response and the level of resistance to challenge S. mansoni infection. Development of protective immunity was also examined in mice with various immune defects, to determine whether these responses are relevant to resistance in this model. Animals with defective specific immediate hypersensitivity response due to deficiencies in IgE (SJL/J) or mast cell (W/Wv) production displayed strong resistance as a result of immunization. Likewise, mice bearing the lpsd (C3H/HeJ) or xid (CBA/N) mutations, affecting cellular or humoral response to certain thymus-independent antigens, developed significant levels of resistance after immunization. A/J mice, with defects in cellular recognition of bacterial endotoxin as well as deficiencies in natural killer cell activity and complement function, also showed significant protective immunity. Thus, these reactivities do not appear to be essential to the resistance against S. mansoni induced by the nonliving vaccine. Two nonresponder strains were identified, P and BALB/c. P mice were defective in specific delayed hypersensitivity response as well as resistance to infection. However, BALB/c mice showed no obvious immune deficiencies at the time of challenge. These results agreed with previous findings in mice immunized by exposure to radiation-attenuated cercariae with one exception; BALB/c mice were protected by vaccination with irradiated cercariae but not by the nonliving vaccine. Thus, further examination of immune response in mice identified in this study as high and low responder strains should allow characterization of critical immune resistance mechanisms induced by the nonliving vaccine, as well as immune mechanisms operating in common between these two models of resistance to S. mansoni.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084645

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Human immune responses to Schistosoma mansoni vaccine candidate antigens.

Authors:  A Ribeiro de Jesus; I Araújo; O Bacellar; A Magalhães; E Pearce; D Harn; M Strand; E M Carvalho
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Parasite exposure elicits a preferential T-cell response involved in protective immunity against Eimeria species in chickens primed by an internal-image anti-idiotypic antibody.

Authors:  B S Bhogal; E B Jacobson; H Y Tse; D M Schmatz; O J Ravino
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

3.  Genetic complementation of defects in vaccine-induced immunity against Schistosoma mansoni in P- and A-strain inbred mice.

Authors:  R Correa-Oliveira; S L James; A Sher
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

4.  Host mouse strain is not selective for a laboratory adapted strain of Schistosoma mansoni.

Authors:  Walter A Blank; Shi Fan Liu; Jayendra Prasad; Ronald E Blanton
Journal:  J Parasitol       Date:  2010-11-19       Impact factor: 1.276

5.  Effect of cholera toxin on vaccine-induced immunity and infection in murine schistosomiasis mansoni.

Authors:  A A Akhiani; L A Nilsson; O Ouchterlony
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

6.  Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen.

Authors:  E J Pearce; S L James; S Hieny; D E Lanar; A Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

Review 7.  Do schistosome vaccine trials in mice have an intrinsic flaw that generates spurious protection data?

Authors:  R Alan Wilson; Xiao-Hong Li; William Castro-Borges
Journal:  Parasit Vectors       Date:  2016-02-17       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.